SCHEMBL10150262

SCHEMBL10150262

CC1C/C=C/CC/C=C/C(=NOCc2ccccc2)Cc2cc(O)cc(O)c2C(=O)O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 6/20 0.51
F13A1 P00488 1/20 0.49
TGM2 P21980 1/20 0.49
HSP90AB1 P08238 2/20 0.48
FLT3 P36888 6/20 0.42
CCNA2 P20248 4/20 0.42
CDK2 P24941 4/20 0.42
CCNA1 P78396 4/20 0.42
MKNK1 Q9BUB5 3/20 0.42
PLK4 O00444 2/20 0.42
CDK1 P06493 2/20 0.42
AXL P30530 2/20 0.42
CDK5 Q00535 2/20 0.42
PRKCE Q02156 2/20 0.42
GEMIN4 P57678 1/20 0.41
HSF1 Q00613 1/20 0.41
NPC1 O15118 1/20 0.41
MITF O75030 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150880 0.93 MKNK2 (0.49) MKNK2F13A1TGM2HSP90AB1FLT3
SCHEMBL10150310 0.90 F13A1 (0.40) MKNK2F13A1TGM2HSP90AB1FLT3
SCHEMBL10150320 0.89 F13A1 (0.39) MKNK2F13A1TGM2HSP90AB1FLT3
SCHEMBL10150309 0.89 F13A1 (0.39) MKNK2F13A1TGM2HSP90AB1FLT3
SCHEMBL10150278 0.89 MKNK2 (0.46) MKNK2F13A1TGM2HSP90AB1FLT3
SCHEMBL12142299 0.88 HSP90AB1 (0.64) MKNK2F13A1TGM2HSP90AB1MAPT
SCHEMBL13049779 0.88 HSP90AB1 (0.64) MKNK2F13A1TGM2HSP90AB1MAPT
SCHEMBL10150154 0.88 HSP90AB1 (0.64) MKNK2F13A1TGM2HSP90AB1MAPT
SCHEMBL10150265 0.86 MKNK2 (0.57) MKNK2F13A1TGM2HSP90AB1FLT3
SCHEMBL10150855 0.85 MKNK2 (0.38) MKNK2F13A1TGM2HSP90AB1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-8329683-B2 Treatment of neurofibromatosis with radicicol and its derivatives NEXGENIX PHARMACEUTICALS, LLC (US) 2012-12-11 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 HSP90AB1, HSP90AA1, HSP90AB2P MKNK2 12/4885F13A1 3067/4885TGM2 3060/4885
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives HSP90AB2P, HSP90AA1, HSPA2 MKNK2 2172/4885F13A1 764/4885TGM2 1861/4885
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 HSP90AB1, HSP90AA1, HSP90AB2P MKNK2 12/4885F13A1 3067/4885TGM2 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.